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Abstract
Background: The polyunsaturated fatty acid (PUFA) composition of (nerve) cell membranes may be involved in the
pathophysiology of depression. Studies so far, focussed mainly on omega-3 and omega-6 PUFAs. In the present study,
saturated fatty acids (SFAs), monounsaturated fatty acids (MUFAs) and PUFAs of the omega-3, -6 and -9 series in plasma and
erythrocytes of patients with recurrent major depressive disorder (MDD-R) were compared with controls.
Methodology and Principal Findings: We carried out a case-control study. The sample consisted of 137 patients with MDD-
R and 65 matched non-depressed controls. In plasma and erythrocytes of patients with MDD-R the concentrations of most
of the SFAs and MUFAs, and additionally erythrocyte PUFAs, all with a chain length .20 carbon (C) atoms, were significantly
lower than in the controls. In contrast, the concentrations of most of the shorter chain members (#18C) of the SFAs and
MUFAs were significantly higher in the patients. Estimated activities of several elongases in plasma of patients were
significantly altered, whereas delta-9 desaturase activity for C14:0 and C18:0 was significantly higher.
Conclusions/Significance: The fatty acid status of patients with MDD-R not only differs with regard to omega-3 and omega-
6 PUFAs, but also concerns other fatty acids. These alterations may be due to: differences in diet, changes in synthesizing
enzyme activities, higher levels of chronic (oxidative) stress but may also result from adaptive strategies by providing
protection against enhanced oxidative stress and production of free radicals.
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Introduction
Major depressive disorder (MDD) -in particular its recurrent,
chronic form (MDD-R)- is ranked as a major cause of disability
and excess mortality worldwide [1]. Moreover, mortality studies
indicate that cardiovascular disease (CVD) accounts for more
excess death in MDD patients than any other single cause [2].
Fatty acids (FAs) may play a key role in the pathogenesis of both
MDD and CVD and so could explain their mutual association [3].
Reported alterations in FAs in MDD include a low omega (v)-3
polyunsaturated fatty acid (PUFA) intake, a decrease in v-3
PUFAs and increased v-6/v-3 PUFA ratios in plasma, erythro-
cytes, adipose tissue and post mortem brain tissue [4,5,6]. The
nature of these FA alterations still has to be elucidated [7].
PUFAs are essential constituents of the human brain and involved
in the regulation of cognition and emotion [8]. PUFAs of the v-3 and
v-6 series are key components of (nerve) cell membrane phospho-
lipids (PLs) and synapses and are responsible for: signal transduction,
ion transport and receptor sensitivity (e.g. for serotonin, dopamine,
endocannabinoids) [9]. Important members of the v-3 and v-6 series
are eicosapentaenoic acid (EPA, C20:5 v-3) and arachidonic acid
(AA,C20:4v-6) which are precursorsfor eicosanoids (prostaglandins,
leukotrienes, thromboxanes) which mediate infection, inflammation
and haemostasis. Importantly, AA derived eicosanoids have a
stimulatory effect while EPA derived eicosanoids have a suppressive
effect on these processes. Furthermore, docosahexaenoic acid (DHA,
C22:6 v-3) derived docosanoids (resolvins, neuroprotectins) have a
neuroprotective effect [8,9,10].
Humans are dependent on their diet for the intake of the two
major 18 carbon (C) chain precursors of the v-3 and v-6 series of
FAs: a-linolenic acid (ALA, C18:3 v-3) and linoleic acid (LA,
C18:2 v-6). Both ALA and LA are transformed by elongases and
desaturases to longer chain PUFAs containing three to six double
bonds (Fig. 1) [10,11].
Delta (D)6 and D5 desaturases introduce double bonds in the v-
3 and v-6 PUFAs; D9 desaturases synthesize monounsaturated
PLoS ONE | www.plosone.org 1 May 2010 | Volume 5 | Issue 5 | e10635Figure 1. Pathways of fatty acid metabolism. Due to figure dimension restrictions, the conversion of C16:0 to C16:1 v-7 could not be depicted.
Abbreviations used: Elongase (Elo), Desaturase (D).
doi:10.1371/journal.pone.0010635.g001
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Elongation to long chain (LC) FAs with up to 22 Cs and very long
chain (VLC) FAs with .22 Cs occurs in the endoplasmatic
reticulum by elongases [11,13]. Because there is only limited
(,15%) conversion of ALA to EPA and DHA and from LA to AA,
while the v-3 and v-6 PUFAs compete for the same desaturases
and elongases, a well balanced v-6/v-3 diet is important to reach
a sufficient FA status [14]. An v-6/v-3 PUFA ratio of ,4:1 is
thought to represent a healthy balance. Fatty fish is the major
source of v-3 PUFAs in humans. In Western industrialized
countries increases in dietary v-6 FA intake and reductions in v-3
FA has changed the v-6/v-3 FA ratio to an estimated 15:1 [15].
Plasma FA levels reflect recent dietary intake while longer-term
dietary impact is better reflected in erythrocyte (membrane) and
adipose tissue FA composition [16]. Moreover FA status depends
not only on dietary intake, but also on endogenous metabolism.
The relationship between intake and incorporation into peripheral
tissues was found to be non-linear and modulated by genetic
factors, age, gender and oxidative stress generated by life style
(stress, smoking, use of alcohol, physical activity) [7,16].
An important limitation of earlier studies on FA levels in MDD
is that they mostly addressed only v-3 and v-6 PUFA levels. They
did not measure the whole FA spectrum, neither were estimates of
their respective desaturases and elongases routinely reported
[4,5.7]. Moreover, these studies focussed mainly on patients
suffering from a single depressive episode while MDD is
increasingly considered as a recurrent and often chronic disorder
rather than a single episode disorder [17]. Data regarding the FA
metabolism of patients with recurrent depression is currently
lacking. We hypothesize that -compared to non-depressed
controls- patients with MDD-R would have lower PUFA levels
and a higher v-6/v-3 ratio and that these alterations are ‘‘trait’’
dependent, i.e. independent of the current depressive status.
We previously compared FA levels in plasma and erythrocytes
of 44 patients randomly chosen out of a cohort of 137 MDD-R
patients with laboratory reference values [18]. We subsequently
analyzed the FA spectrum and estimated activities of their
respective desaturases and elongases of the whole cohort and
compared them with a matched healthy control group (n=65).
Materials and Methods
Population
Recurrently depressed patients participated in a randomized
clinical trial comparing the efficacy of preventive cognitive therapy
on relapse and recurrence (DELTA Study). The background and
methodology have been described elsewhere [17]. In brief, the
inclusion criteria of the trial were: age between 18 and 65 years, at
least two depressive episodes in the previous 5 years, and having
reached current remission status according to the criteria of fourth
edition of the Diagnostic and Statistical Manual. Exclusion criteria
were current or previous mania or hypomania (bipolar illness), any
psychotic disorder (current or previous), organic brain damage,
alcohol or drug abuse, predominant anxiety disorder, recent ECT,
recent cognitive treatment or receiving CT at the start of the study
or current psychotherapy with a frequency of more than two times
a month. The medical ethical committee of the Academic Medical
Centre approved the study protocol.
At the 2-years follow up of the original trial, the patients
participated in the current study, so patients were either in a
relapse (depressed) or a remission (non-depressed). Furthermore,
we recruited age and gender matched, healthy, non-depressed
control subjects by advertising. All participants provided written
informed consent prior to enrolment.
Assessment of depression and other variables
For the current study the psychiatric status was assessed with the
Structured Clinical Interview of DSM-IV disorders (SCID-I) by
trained interviewers [19]. Information about the use of antide-
pressants during sampling was obtained by the Trimbos/IMTA
questionnaire for Costs associated with psychiatric illness (TIC-
P:40) and by interview [20]. Furthermore, blood was sampled in
the non fasting state and anthropometric measurements were
taken, including: body mass index (BMI; kg/m2), WC in cm and
waist to hip ratio (WHR). WC was measured at the level midway
between lower rib and the iliac crest, with participants in standing
position.
Blood sample collection and analysis of FAs
FAs in plasma and washed erythrocytes were analyzed by
capillary gas chromatography, as described previously [18,21].
Plasma was separated within 4 h of collection and stored at
280uC until analysis. Total FAs in plasma and washed
erythrocytes were expressed as mmol/L and pmol/10e6 erythro-
cytes respectively. FAs were analyzed both quantitatively and
qualitatively. Qualitative analysis of FAs as a percentage of total
FAs may be misleading; because the consequence of this approach
is that an increase in one FA results in a relative decrease in other
FAs to maintain 100% [16]. Therefore we chose to present the
results in concentrations. The analysis in percentages is given in
supplementary tables (S1, S2). The estimated activities (or
surrogate measures) of D5, D6 and D9 desaturases and elongases
in plasma are expressed as product/precursor ratios. We do not
estimate these activities in erythrocytes because they are reported
to be incapable of chain elongation or desaturation of FAs [16].
Statistical analysis
Statistical analyses were performed using SPSS version 16.0
(SPSS Inc., Chicago, IL, USA). Continuous demographic data of
the patients with MDD-R and non-depressed matched controls
were analyzed using independent means t-tests and x
2 tests were
used for categorical variables. Additional tests with correction for
WC were performed by the use of ANCOVA’s. ANOVA’s were
also performed in additional, explorative analyses to test whether
FA concentrations differed between patients with continuous,
intermittent or without use of anti-depressant medication.
Independent means t-tests were performed to detect differences
in FA concentrations between currently depressed and non-
depressed patients.
In FA research, multiple tests have to be performed because of
the many members of the different FA series. Therefore the results
should be interpreted cautiously with regard to type I errors. We
have chosen not to adjust our p-value for multiple testing for the
following reasons. First, although our research was partly
exploratory (with regard to FA series other than the v-3 and v-
6), the main part of the analyses (the v-3 and v-6 series) was
hypothesis driven. Second, it is not common practice in FA
research to adjust the p-value for multiple testing. Third,
adjustment for multiple testing may induce type II errors.
Results
Sample characteristics of the patients and the non-depressed
control group are displayed in Table 1. Body weight, BMI, WC
and WHR were significantly higher in MDD-R patients,
compared to non-depressed controls. Patients had a lower
education level, smoking habits did not differ. Information on
anti-depressant use of the MDD-R patients is given in Table 2.
Fatty Acids and MDD-R
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The sums of total FAs, SFAs, MUFAs and PUFAs were all
significantly (p,.001) higher in the recurrently depressed patients
than in the non-depressed control subjects.
The sum of the FAs of the v-3 series in plasma did not differ
between patients and controls; the concentration of the precursor
C18:3 v-3, was higher (p,.05), while levels of EPA and DHA
were similar in patients and controls. The sum of v-6 PUFAs was
significantly higher in patients (p,.001) and the concentration of
the v-6 series precursor linoleic acid (C18:2 v-6) and the next
member (C18:3 v-6) were significantly higher in the patients
(p,.001, p,.05). The concentrations of other members of the v-6
series did not differ significantly between patients and controls.
The concentration of the MUFA C14:1 v-5 was significantly
higher in patients’ plasma than in controls (p,.001). The sum of v-7
MUFAs was significantly higher in the patients (p,.001) as were the
first two members of the v-7 series, C16:1 v-7 and C18:1 v-7, but
C20:1 v-7 was similar in patients and controls. The sum of v-9
MUFAsandthefirsttwomembersC16:1v-9 and C18:1 v-9 were all
significantly higher in the patients than in controls (p,.001).The
concentration of C20:1 v-9 was similar, but levels of C22:1 v-9 and
C24:1 v-9 were both significantly lower in the patients (p,.001).
The plasma SFAs concentrations of C14:0 and C18:0 were both
significantly higher (p,.001), but concentrations of C20:0 and
C22:0 were significantly lower in patients than in controls (p,.01).
FAs in erythrocytes (Table 4)
Compared to healthy controls, the sums of total FAs and PUFAs
were significantly (p,.001) lower in the MDD-R patients, while
the sums of SFAs and MUFAs were similar.
The sum of v-3 PUFAS in erythrocytes was significantly lower
in patients than in controls (p,.001). The v-3 precursor C18:3 v-
3 did not differ but its D6 desaturase product C18:4 v-3 was
Table 1. Demographic and clinical characteristics of MDD-R
patients and the matched non-depressed control group.
Controls
(n=65)
MDD-R
(n=137)
p-
value
a
Age (years 6 SD) 44694 4 610 ns
Male sex (% (n/N)) 28% (18/65) 26% (35/137) ns
Weight (kg 6 SD) 73613 79616 *
BMI 6 SD 24.563.5 26.865.2 ***
WC (cm 6 SD) 83.7612.2 89.3613.8 **
WHR 6 SD 0.8160.08 0.8560.08 **
Smoking (% (n/N)) 22.6% (14/62) 31.0% (35/113) ns
Education (% (high/middle/low)) 74.6/20.3/5.1 35.3/30.9/33.8 ***
Current depression (%) 0% (0/65) 19% (26/136) ***
aIndependent means t-tests or x
2 tests: significantly different in comparison to
controls at * p,.05, ** p,.01, *** p,.001.
MDD-R, Major Depressive Disorder, Recurrent form; BMI, Body Mass Index; WC,
Waist Circumference; WHR, Waist-to-Hip Ratio.
doi:10.1371/journal.pone.0010635.t001
Table 2. Anti-depressant use of MDD-R patients.
Subcategory Result (% (n/N))
Current use of anti-depressants 63% (81/129)
Type of current anti-depressant TCA 9% (7/81)
SSRI 65% (53/81)
SNRI 19% (15/81)
Antidepressant
and/or lithium
6% (5/81)
Other 1% (1/81)
TCA, Tricyclic Anti-Depressants; SSRI, Selective Serotonin Reuptake Inhibitors;
SNRI, Serotonine Noradrenaline Reuptake Inhibitors.
doi:10.1371/journal.pone.0010635.t002
Table 3. Plasma fatty acid concentrations (mmol/l) of MDD-R
patients compared with a matched non-depressed control
group
a.
Controls
(n=65) MDD-R (n=137)
Linolenic acid (C18:3 v-3) 63640 79645*
Octadectetraenoic acid (C18:4 v-3) 1.561.9 1.462.6
Eicosapentaenoic acid (C20:5 v-3) 67644 73644
Docosapentaenoic acid (C22:5 v-3) 34611 31612
Docosahexaenoic acid (C22:6 v-3) 130653 125647
S omega-3 PUFAs 2956110 3096111
Linoleic acid (C18:2 v-6) 30406685 36296894***
Gamma-linolenic acid (C18:3 v-6) 47620 57634*
Homogamma linolenic acid (C20:3 v-6) 156694 159665
Arachidonic acid (C20:4 v-6) 5546165 5726162
Docosatetraenoic acid (C22:4 v-6) 14651 4 66
Docosapentaenoic acid (C22:5 v-6) 9649 65
Eicosadienoic acid (C20:2 v-6) 19610 2167
Docosadienoic acid (C22:2 v-6) 0.060.0 5.267.2***
S omega-6 PUFAs 38406785 448161015***
Myristoleic acid (C14:1 v-5) 8.867.5 21.3623.5***
Palmitoleic acid (C16:1 v-7) 2426124 3886280***
Vaccenic acid (C18:1 v-7) 163646 198663***
13-eicosenoic acid (C20:1 v-7) 13679 621
S omega-7 PUFAs 4186168 5956333***
Hypogeic acid (C16:1 v-9) 42615 55623***
Oleic acid (C18:1 v-9) 19756722 243961033***
Gondoic acid (C20:1 v-9) 14661 5 68
Erucid acid (C22:1 v-9) 12684 67***
Nervonic acid (C24:1 v-9) 64620 54612***
Eicosatrienoic acid (C20:3 v-9) 10651 0 67
S omega-9 PUFAs 21106754 257861057***
Myristic acid (C14:0) 146674 2136163***
Pentadecanoic acid (C15:0) 30693 4 616
Palmitic acid (C16:0) 26516707 316361271***
Stearic acid (C18:0) 7416174 7876242
Arachidic acid (C20:0) 25.566.1 28.567.9**
Behenic acid (C22:0) 58612 53613**
Lignoceric acid (C24:0) 38683 7 69
S Saturated fatty acids
b 36606942 429761642***
S Monounsaturated fatty acids 25276881 318361365***
S Polyunsaturated fatty acids 41456837 480161077***
S Total fatty acids 1038262442 1227363836***
aIndependent means t-tests: significantly different in comparison to controls at
*p ,.05, ** p,.01, *** p,.001.
bC15:0 excluded due to missing values.
doi:10.1371/journal.pone.0010635.t003
Fatty Acids and MDD-R
PLoS ONE | www.plosone.org 4 May 2010 | Volume 5 | Issue 5 | e10635significantly higher in patients than in controls (p,.001). EPA
concentrations were not different but C22:5 v-3 -the elongase
product of EPA- and DHA were both significantly lower in the
patients (p,.001).
Analogous to the sum of v-3 PUFAs, the sum of v-6 PUFAs in
the erythrocytes was also significantly lower in the patients than in
the control subjects (p,.001). The concentration of the precursor
C18:2 v-6 was similar, while the concentration of its D6 desaturase
product C18:3 v-6 was significantly higher in patients than in
controls (p,.001). The subsequent members of the v-6 series: AA,
C22:4 v-6 and C22:5 v-6 were all significantly lower (p,.001) in
the patients.
The concentration of the erythrocyte MUFA C14:1 v-5 was
significantly lower in the patients than in the control subjects
(p,.001). In the v-9 series C24:1 v-9 (nervonic acid) and the sum
of the v-9 FAs were significantly lower in the patients (p,.001).
The levels of SFAs C14:0 and C18:0 were similar but levels of
C20:0, C22:0 and C24:0 were all significantly lower in the patients
(p,.001).
Ratios, desaturases and elongases (Table 5, 6, 7)
The various ratios between the sums of SFA, MUFAs, PUFAs,
v-3 and v-6 PUFAs and AA/EPA and AA/DHA in the plasma
did not differ between the patients and control subjects (Table 5).
In the erythrocyte, the ratios of the S SFA/S PUFA, the S
MUFA/S PUFA, and S SFA/S MUFA and the Sv -6/Sv -3
PUFAs were higher in the patients but the AA/EPA and the AA/
DHA ratios did not differ (Table 6).
The estimated activities of desaturases and elongases in plasma
are given in Table 7. D6 and D5 desaturases did not differ in their
activity. The estimated activity of the D9 desaturases (C14:1 v-5/
C14:0 and C18:1 v-9/C18:0) was significantly higher in patients
than in the control subjects (p,.001), but C24:1 v-9/C24:0 was
significantly lower (p,.01).
In the v-3 series the estimated activity of the elongase C22:5 v-
3/C20:5 v-3 was significantly lower in the patients with MDD-R
(p,.01). In the v-9 series, the activity of the elongase C22:1 v-9/
C20:1 v-9 was significantly lower, but the activity of the next
elongase C24:1 v-9/C22:1 v-9 was significantly higher in the
patients compared to controls (p,.001). The estimated activities of
elongases in the v-7 series (C18:1 v-7/C16:1 v-7 and C20:1 v-7/
C18:1 v-7) were significantly lower in the patients. The estimated
activity of elongase C22:0/C20:0 was significantly lower and the
elongase C24:0/C22:0 significantly higher in the patients
(p,.001).
Adjustment for waist circumference (Table 8)
Adjustment for WC as a characteristic of the Metabolic
Syndrome (MetS), did not alter the significance of the differences
between the concentrations of the FAs in the erythrocytes of the
patients compared to the controls [We divided the p-values in four
categories (p$0.05, p,0.05, p,0.01, p,0.001); no altering of
significance means the p-value remained in the same category]. In
plasma, the significance was altered for the differences in the
concentrations of the following plasma FAs [C14:0, C16:0, C20:0,
C16:1 v-7, C18:1 v-7, C16:1 v-9, C18:1 v-9 and C18:3v-3
(ALA)] between patients with MDD-R and controls (Table 8).
Influence of anti-depressant use
To explore whether use of antidepressants was associated with
different FA patterns we performed explorative ANOVA’s,
comparing three groups of patients: 1) those who had used
antidepressants continuously, 2) intermittent or 3) not at all. No
differences in FA concentrations between these groups were found,
except for C22:5 v-3 in plasma (resp. 30.94 vs. 27.47 vs. 34.26,
p,0.05) and C18:3 v-3 (0.97 vs. 0.75 vs. 0.83, p,0.05) and 20:5
v-3 (3.99 vs. 2.92 vs. 3.29, p,0.05) in erythrocyte membranes.
Influence of current depressive status
In the group of patients with recurrent depression, and FA
concentrations of the patients with a current depression (n=26)
were compared with those of the non-depressed (n=110) using
Table 4. Erythrocyte fatty acid concentrations (pmol/10e6
erythrocytes) of MDD-R patients compared with a matched
non-depressed control group
a.
Controls
(n=65) MDD-R (n=137)
Linolenic acid (C18:3 v-3) 0.8160.32 0.8460.31
Octadectetraenoic acid (C18:4 v-3) 0.03560.11 0.2160.27***
Eicosapentaenoic acid (C20:5 v-3) 3.962.0 3.361.6
Docosapentaenoic acid (C22:5 v-3) 10.562.1 7.961.5***
Docosahexaenoic acid (C22:6 v-3) 20.166.6 14.864.2***
S omega-3 PUFAs 35.3610 26.966.4***
Linoleic acid (C18:2 v-6) 67612 66613
Gamma-linolenic acid (C18:3 v-6) 0.3860.37 0.5760.21***
Homogamma linolenic acid (C20:3 v-6) 9.762.1 8.862.4*
Arachidonic acid (C20:4 v-6) 81.668.7 71.5610.5***
Docosatetraenoic acid (C22:4 v-6) 13.062.5 10.762.6***
Docosapentaenoic acid (C22:5 v-6) 2.160.6 1.760.6***
Eicosadienoic acid (C20:2 v-6) 1.360.4 1.360.4
Docosadienoic acid (C22:2 v-6) 060 0.3760.43***
S omega-6 PUFAs 175619.9 161.4619.0***
Myristoleic acid (C14:1 v-5) 0.6060.66 0.2560.31***
Palmitoleic acid (C16:1 v-7) 2.561.3 3.061.5*
Vaccenic acid (C18:1 v-7) 7.961.4 7.561.5
13-eicosenoic acid (C20:1 v-7) 0.2760.35 0.2160.29
S omega-7 PUFAs 10.662.3 10.662.5
Hypogeic acid (C16:1 v-9) 1.963.0 0.960.6*
Oleic acid (C18:1 v-9) 75610 74610
Gondoic acid (C20:1 v-9) 1.260.4 1.260.4
Erucid acid (C22:1 v-9) 2.161.4 1.962.2
Nervonic acid (C24:1 v-9) 19.663.5 13.363.4***
Eicosatrienoic acid (C20:3 v-9) 0.3160.24 0.3660.24
S omega-9 PUFAs 100613 92610***
Myristic acid (C14:0) 3.561.2 3.361.0
Palmitic acid (C16:0) 156619 164623*
Stearic acid (C18:0) 104611 103611
Arachidic acid (C20:0) 2.860.5 2.560.4***
Behenic acid (C22:0) 9.561.6 7.661.5***
Lignoceric acid (C24:0) 21.363.0 14.864.2***
S Saturated fatty acids 297632 295629
S Monounsaturated fatty acids 112614 112614
S Polyunsaturated fatty acids 211623 189618***
S Total fatty acids 620666 588654***
aIndependent means t-tests: significantly different in comparison to controls at
*p ,.05, ** p,.01, *** p,.001.
doi:10.1371/journal.pone.0010635.t004
Fatty Acids and MDD-R
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mean plasma and erythrocyte FA concentrations between the two
groups.
Influence of education level
After correction for differences in educational level (low, middle,
high), the difference in C18:3 v-3 in plasma between patients and
controls, disappeared (6766.3 vs. 7864.2, p=.164). The other
FAs in plasma and erythrocytes were not altered.
Discussion
Previous studies generally focussed on v-3 and v-6 PUFAs in
samples of patients with a single depressive episode or high levels
of depressive symptoms [4,5,7]. In the present study we were able
to compare not only PUFA concentrations of the v-3 and v-6
series, but also v-5, v-7 and v-9 MUFAs, as well as SFAs, in
plasma and erythrocytes of patients with the recurrent type of
MDD with those of matched control subjects.
The results of the present study confirm the results of our
explorative pilot study [18]. Most striking was the finding that the
concentrations of plasma and erythrocyte MUFAs and SFAs and
additionally erythrocyte PUFAs, with a chain length .20 C atoms
were all lower in the patients with MDD-R with the exception of
C24;0 in the plasma and C22:1 v-9 in the erythrocyte which did
nor differ in patients and controls. In contrast, the concentrations
of most of the shorter chain members (#18 C) of all these families
were higher in patients, with the exception of lower concentrations
of C14:1 v-5 and C16:1 v-9 in erythrocytes.
Plasma FA levels reflect the combined effect of recent intake and
endogenous processing [16]. So the increase in SFAs and MUFAs
with #18 C in the patients may reflect the effect of a higher intake
whether or not associated with higher activity of D9 desaturases.
The estimated activities of the D9 desaturases C14:0/C14:1 v-5
and C18:0/C18:1 v-9 in the plasma were significantly higher in
the depressive patients (Table 7). Enhanced D-9 desaturase activity
has also been reported in patients with the MetS [12].
The Sv -6 PUFAs in plasma was significantly higher in the
patients than in the controls consistent with a higher intake of
mainly LA. However, in contrast to many earlier studies, we found
that levels of AA, EPA, DHA and the Sv -3 PUFAs in plasma
were similar in patients and controls, as were AA/EPA and AA/
DHA ratios [4,5,7]. Also estimated activities of D5 and D6
desaturases did not differ.
In the erythrocytes of our MDD-R patients the sums of v-3 and
the v-6 PUFAs were lower and the ratios Sv -6/Sv -3 were
higher than in controls corresponding with many reported data
[4,5,7]. But as in plasma, the ratios AA/EPA and AA/DHA did
not differ between patients and controls. The increase in the D6
desaturase products C18:4 v-3 and C18:3 v-6 might be
compensatory to the decreases in C22:5 v-3, C22:6 v-3 and
Table 5. Several ratios of fatty acids concentrations in plasma
of MDD-R patients compared with a matched non-depressed
control group
a.
Controls (n=65) MDD-R (n=137)
S SFAs/S PUFAs 1.15460.169 1.17260.232
S MUFAs/S PUFAs 0.60360.147 0.65260.178
S SFAs/S MUFAs 0.88560.143 0.88960.202
S omega-6/S omega-3 14.3764.59 15.7964.80
C20:4 v-6/C20:5 v-3 11.5667.38 10.5866.20
C20:4 v-6/C22:6 v-3 4.88762.366 5.01061.7062
aIndependent means t-tests: significantly different in comparison to controls at
*p ,.05, ** p,.01, *** p,.001.
doi:10.1371/journal.pone.0010635.t005
Table 6. Several ratios of fatty acids concentrations in
erythrocytes of MDD-R patients compared with a matched
non-depressed control group
a.
Controls (n=65) MDD-R (n=137)
S SFAs/S PUFAs 1.41460.065 1.57260.128***
S MUFAs/S PUFAs 0.52960.043 0.54860.057*
S SFAs/S MUFAs 2.68461.773 2.88460.232***
S omega-6/S omega-3 5.43762.363 6.37761.773**
C20:4 v-6/C20:5 v-3 27.45616.79 26.41612.71
C20:4 v-6/C22:6 v-3 5.14965.863 5.23261.701
aIndependent means t-tests: significantly different in comparison to controls at
*p ,.05, ** p,.01, *** p,.001.
doi:10.1371/journal.pone.0010635.t006
Table 7. Several indices of desaturases and elongases in
plasma of MDD-R patients compared with a matched non-
depressed control group
a.
Controls
(n=65) Delta (n=137)
Delta-6 omega-3 (C18:4n-3/C18:3n-3) 0.02960.039 0.02360.039
Delta-5 omega-3 (C20:5n-3/C18:4n-3) 25.25617.56 26.96621.6
Delta-6 omega-3 (C22:6n-3/C22:5n-3) 3.9961.44 4.3361.49
Elongase (C22:5n-3/C20:5n-3) 0.6660.34 0.5260.25**
Delta-6 omega-6 (C18:3n-6/C18:2n-6) 0.01660.007 0.01660.008
Delta-5 omega-6 (C20:4n-6/C20:3n-6) 3.9461.22 3.9561.45
Delta 6 omega-6 (C22:5n-6/C22:4n-6) 0.6760.16 0.6560.22
Elongase (C20:3n-6/C18:3n-6) 3.8162.67 3.4763.05
Elongase (C22:4n-6/C20:4n-6) 0.02560.007 0.02460.007
Delta-9 (C14:1n-5/C14:0) 0.05260.032 0.10360.114***
Delta-9 (C16:1n-7/C16:0) 0.0260.003 0.0260.02
Delta-9 (C18:1n-9/C18:0) 2.6460.55 3.1060.77***
Delta-9 (C24:1n-9/C24:0) 1.71460.485 0.52960.380**
Elongase (18::1 n-9/C16:1 n-9) 54.20647.88 55.02664.23
Elongase (C20:1 n-9/C18:1n-9) 0.00760.002 0.00760.006
Elongase (22:1 n-9/C20:1 n-9) 0.9060.71 0.3360.61***
Elongase (C24:1 n-9/C22:1n-9) 7.7066.56 13.6266.90***
Elongase (C18:1n-7/C16:1n-7) 0.7760.25 0.6560.28**
Elongase (C20:1n-7/C18:1n-7) 0.0860.04 0.0560.10*
Elongase (C16:0/C14:0) 20.6266.26 18.2666.54*
Elongase (C18:0/C16:0) 0.2860.04 0.2860.29
Elongase (C20:0/C18:0) 0.03560.05 0.03760.009*
Elongase (C22:0/C20:0) 2.3260.36 1.9760.57***
Elongase (C24:0/C22:0) 0.6560.069 0.7160.12***
aIndependent means t-tests: significantly different in comparison to controls at
*p ,.05, ** p,.01, *** p,.001.
doi:10.1371/journal.pone.0010635.t007
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MetS [14,22].
So, part of our most marked findings may be explained by the
fact that based on plasma levels, the patients with MDD-R
consume more SFAs and MUFAs and v-6 PUFAs, C18:2 v-6
(LA) in particular. The increase in the levels of C22:2 v-6
(docosadienoic acid) in plasma and erythrocytes of the patients
may also be explained thereby [23].
To our knowledge, concentrations of the longer chain FAs
($20–24 C) of SFAs and MUFAs and estimates of their elongases
were not systematically addressed in patients with MDD. We
found a significant decrease of the .20 C plasma SFAs and
MUFAs and of all the .20 C erythrocyte FA levels, with the
exception of plasma C24:0 and erythrocyte C22:1 v-9 which were
similar in patients and controls.
One explanation may be altered elongase activity (Table 7).
Interestingly, our results show decreased elongase activity on 20C
FAs, whereas elongases acting on 22C FAs show increased activity,
with the exception of the v-6 series. However, the use of FA ratio’s
for enzyme activity estimation gives only ‘‘surrogate’’ measures
and may not reflect real activity [16].
Although not often reported, VLC SFAs and MUFAs, mainly
C24:0 (lignoceric acid) and C24:1 v-9 comprise 1–6% of total
plasma PLs. These fatty acids are very abundant (up to 46 mol%)
in sphingomyelin. In lower concentration (approximately 0.11–
0.015) are FAs with 26 carbons such as C26:0 and C26:1 v-9 and
C26:2 v-6. These fatty acids are also typically found in the
sphingomyelin fraction [16].
We would like to hypothesize that the decreases in the longer
chain FAs could be related to the use of these longer chain FAs for
increased ceramide and sphingolipid synthesis as seen in insulin
resistance and MetS [24]. Furthermore, these long chain SFAs
could be used for production of C26:0. High levels of C26:0 in
whole blood were recently shown to be associated with the MetS
in Japanese men [25].
Taken together, the cause of the decrease in concentrations of
plasma and erythrocyte MUFAs and SFAs and additionally
erythrocyte PUFAs, all with a chain length of $20 C atoms may
well be multifactorial, that is to say modulated by dietary factors,
life style, decreased or impaired activity of their respective
desaturases and elongases, but could also correspond with
decreased or increased incorporation in and/or enhanced
detachment from the various plasma lipid components and/or
cell membranes. Further research is needed to differentiate
between these possibilities.
Consistent with the literature on obesity in depressive disorders,
BMI, WHR and WC were all significantly higher in our MDD-R
patients than in the control subjects [26]. The MetS criterion of an
increased WC ($88 cm in women and $102 cm in men) was met
in 44 of the 102 female patients (mean 87; range 63–122).
Adjustment for WC, as a peripheral indicator of insulin resistance
associated with visceral fat, resulted in reduced significances of the
differences in most of the short chain members of the FA series in
plasma (Table 8). This may correspond with the presence of the
MetS and/or associated factors such as the dietary composition.
However, the differences found in the longer chain plasma FAs
and all differences in the erythrocyte were not altered by
adjustment for WC. So, our main finding of lower concentrations
of the longer members of the various FA series can not merely be
explained by the presence of the MetS, and may reflect other
MDD-R associated factors.
In this study after correction for differences in educational level
(low, middle, high), the difference in C18:3 v-3 in plasma between
patients and controls disappeared, but the other FAs in plasma
and erythrocytes were not altered. The percentage of smokers vs.
non-smokers did not differ between patients and controls and so
are not likely to be responsible for the differences in FA
concentrations.
Antidepressant (AD) use was accompanied by altered concentra-
tions of a small number of v-3 PUFAs (C18:3 v-3 and C20:3 v-3 in
plasma and C22:5 v-3 in the erythrocyte membrane), other FA
concentrations were not altered. There may be several explanations
suchas: thepresence ofa more serious depressionin the ADusers, the
consumption of more food and less physical activity as well as an
effect of AD on FA metabolism and (oxidative) stress. To our
knowledge data of the direct effects of AD on FAs are still lacking and
reports on the effect of AD on oxidative stress are sparse and still
inconsistent [27]. Our study was not directed at these aspects so we
refrain from drawing conclusions.
We found no influence of current depressive status on FA
concentrations, so they seem to be state-independent. This may
indicate that the FA alterations in this study could represent a
biological ‘‘trait’’ marker for recurrent depression (MDD-R).
An essential characteristic of MDD-R is the presence of
increased oxidative stress, which may also modulate FA alterations
in our patients. Oxidative stress is the result of an imbalance
Table 8. Plasma fatty acid concentrations (mmol/l) of MDD-R patients compared with a matched non-depressed control group,
with and without correction for waist circumference
a.
Controls
b (n=65) MDD-R
b (n=137) Controls (n=65) MDD-R (n=137)
Linolenic acid (C18:3 v-3) 67.3865.6 77.2263.9 63640 79645*
Palmitoleic acid (C16:1 v-7) 267.3629.7 375.2620.6** 2426124 3886280***
Vaccenic acid (C18:1 v-7) 169.567.32 195.665.08** 163646 198663***
Hypogeic acid (C16:1 v-9) 43.7062.63 54.4361.82** 42615 55623***
Oleic acid (C18:1 v-9) 20866116.5 2389680.80* 19756722 243961033***
Myristic acid (C14:0) 157.4617.9 207.1612.4 146674 2136163***
Palmitic acid (C16:0) 27946138.1 3105695.76 26516707 316361271***
Arachidic acid (C20:0) 26.260.96 28.360.66 25.566.1 28.567.9**
aANCOVA’s with correction for WC on the left and independent means t-tests on the right: significantly different in comparison to controls at * p,.05, ** p,.01,
*** p,.001.
bWC corrected values.
doi:10.1371/journal.pone.0010635.t008
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and/or diminished anti-oxidant defence mechanisms. Evidence
for a causal role of oxidative stress in the pathogenesis of
psychiatric diseases including bipolar disorder and depression is
steadily accumulating [28]. The brain is particularly vulnerable
because of its high oxygen consumption and hence generation of
ROS combined with a high PUFA content and modest
antioxidant defences [29].
Enhanced oxidative stress in our patients may be the result of a
cumulative effect of the presence of the MetS and depression
associated factors such as: psychological stress, hypothalamic-
pituitary-adrenal (HPA)-axis hyperactivity, life style changes (v-3
PUFA deficient diet, physical inactivity, alcohol abuse and
smoking). Major depressive disorder -its recurrent, chronic form
in particular- may be accompanied by sustained activation of the
HPA-axis [30,31].
Moreover, mitochondria are the principal ROS producers and
evidence for genetically determined mitochondrial dysfunction in
psychiatric disease, MDD included, is also growing steadily
[32,33]. Mitochondrial dysfunction will further enlarge increased
ROS production and may also explain the increased prevalence of
the MetS and CVD in MDD-R.
Noteworthy, the pattern of FA alterations in our patients are not
specific for MDD-R but is also found in other (psychiatric) diseases
accompanied by increased oxidative stress e.g. bipolar disorder,
schizophrenia, diabetes, Alzheimer’s disease and are also seen
during normal aging [34,35,36,37].
Finally, the FA alterations in MDD-R could fulfil an adaptive or
protective role, as the alterations may render cell membranes less
vulnerable for oxidation. SFAs and MUFAs are more resistant to
oxidative stress, while the more polyunsaturated a FA, the more
susceptible it is [38].
Our study has several distinct limitations: dietary intake of fat
and FAs, alcohol consumption, smoking habits, physical activity
and the presence of the MetS were not systematically assessed. We
used ratios for estimating desaturases and elongases and did not
measure enzyme expression/activities. However, in spite of these
many limitations, our results were quite consistent which may
argue for their validity. This consistency, together with the
magnitude of our findings, also makes type I errors -that could
have occurred because of multiple testing- less likely.
At this moment the basal question; whether fatty acids
alterations in depressive patients are either the cause or the
consequence of the disease, cannot yet be answered on the basis of
available studies (ecologic, observational, and RCTs). They
provide inconsistent data, the very few prospective studies included
[39,40]. In their most recent review, Appleton et al. stressed that in
relation to the effects of v-3 PUFAs, an important distinction may
exist between diagnosed depressive illness and the less severe,
undiagnosed, or precursor ‘‘depressed mood’’ [40].
The best methods to study FAs have not yet crystallized. The
FA composition of the different blood lipid fractions, e.g. plasma,
erythrocytes and platelets is inter-related, particularly for PLs. As
erythrocytes have a life span of approximately 120 days, large
changes that occur within days of altering dietary fat intake can
only be explained by exchange and transfer of FA from plasma to
erythrocytes [16].
Although erythrocyte FA composition is comparable to that of
plasma total PLs, there are differences [16]. Given these
differences it will prove to be more informative to analyse FAs
in both compartments. For prospective studies over several years
FA biomarkers from erythrocytes or adipose tissue, which reflect
longer-term intakes (preceding months or years, respectively)
would be more suitable to test the association between long term
PUFA status and depression [39,40].
Adequately powered intervention studies are urgently needed,
studying the effect dependent on the background FA status and the
change during the study period. Further FA research should
include: dietary questionnaires, analysis of the complete FA
spectrum and also the enzymes involved in their metabolism. It
is increasingly demonstrated that polymorphisms in the genes/
enzymes (desaturases, elongases) that regulate biosynthesis of EPA,
DHA and AA from their precursors (ALA, EPA) may represent
important determinants of plasma and tissue PUFA levels [41].
Measurement of (oxidative) stress levels and lipid peroxidation
products and assessment of MetS symptoms will help us to
distinguish between harmful or adaptive FA changes. It will also
help us to determine whether patients will benefit from anti-
oxidant strategies and/or any form of FA supplementation.
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Table S1 Plasma fatty acid concentrations (% of total fatty acids)
of MDD-R patients compared with a matched non-depressed
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a.
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